StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Biogen (BIIB), Eisai Highlight Detailed Results from Phase II Clinical Study of Elenbecestat at AAIC 2018
July 25, 2018 10:38 AM
Eisai Co., Ltd. and Biogen Inc. (NASDAQ: BIIB) announced detailed results from a Phase II clinical study (Study 202) of ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Management Comments
Next Articles
Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 20
July 25, 2018 10:30 AM
Biogen (BIIB) PT Raised to $392 at Morgan Stanley
July 25, 2018 7:46 AM
Biogen (BIIB) PT Raised to $357 at RBC Capital
July 25, 2018 7:44 AM
Biogen (BIIB) PT Raised to $348 at Baird
July 25, 2018 6:40 AM
Biogen (BIIB) PT Raised to $320 at Barclays
July 25, 2018 3:35 AM
Citron's Left reiterates belief AbbVie shares will fall sharply
July 24, 2018 4:06 PM
Biogen (BIIB) PT Raised to $445 at JPMorgan
July 24, 2018 1:55 PM
S&P reaches highest level since February as Alphabet shares soar
July 24, 2018 7:32 AM
Biogen easily tops Street estimates on Spinraza sales, raises forecast
July 24, 2018 6:42 AM
Biogen (BIIB) Acquires Muscle Enhancement Program from AliveGen
July 24, 2018 6:42 AM
Biogen (BIIB) Tops Q2 EPS by 56c, FY Guidance Tops Consensus
July 24, 2018 6:37 AM
Applied Genetic Technologies (AGTC) Secures $10M Milestone Payment Following Treatment of First Patient of Second Cohort in Phase 1/2 Clinical XLRP Study
July 23, 2018 7:07 AM
